Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug ...
Please provide your email address to receive an email when new articles are posted on . Patients with infectious uveitis are at an increased risk for corneal graft failure compared with patients with ...
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced ...
SAN FRANCISCO and SUZHOU, China, Dec. 22, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA ...
Ocular inflammatory disease, including uveitis, scleritis, and orbital inflammatory disease, can be acute or chronic, infectious, non-infectious, or present as a masquerade syndrome. Therefore, its ...
MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...
Adalimumab had a slight advantage over infliximab in terms of adverse events when used to treat patients with noninfectious uveitis (NIU). Infliximab and adalimumab were found to have similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results